Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Post-COVID-19 syndrome: persistent neuroimaging changes and symptoms 9 months after initial infection
Grach, Stephanie L. , Ganesh, Ravindra , Messina, Steven A. , Hurt, Ryan T. , Ganesh, Ravindra , Grach, Stephanie L

Mayo Clinic

BMJ Case Reports | April 8, 2022 | Volume: 15 | Issue: 4 | Pages: e248448

10.1136/bcr-2021-248448 | PMID 35396239 Get It

A previously healthy and active middle-aged woman acquired COVID-19 as an occupational exposure with subsequent persistent post-COVID-19 symptoms including headache, dyspnoea on exertion, chest pressure, tachycardia, anosmia, parosmia, persistent myalgia, vertigo, cognitive decline and fatigue. She presented to a tertiary medical centre for further evaluation after 9 months of persistent symptoms and had a largely unremarkable workup with the exception of a persistently elevated monocyte chemoattractant protein 1, blunted cardiovagal response and non-specific scattered areas of low-level hypometabolism at the bilateral frontal, left precuneus, occipital and parietal regions on PET scan.
Things that go bump in the night: Neuroradiology emergencies
Weindling, Steven M.

Mayo Clinic

Applied Radiology | April 4, 2022 | Volume: No volume available | Issue: No issue available | Pages: 10-23

10.37549/ar1539 Get It

P156. OPTIMIZING OUTCOMES IN THE MANAGEMENT OF STAGE III AND IV PRESSURE ULCERS
Saleem, Humza Y. , Moran, Steven L. , Vyas, Krishna S. , Thongprayoon, Charat

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 123-123

10.1097/01.gox.0000828964.12056.00 Get It

P107. COMPARISON OF CHEST FEMININITY OF TRANSGENDER WOMEN WITH HORMONE TREATMENT VS. SURGICALLY AUGMENTED WITH BREAST IMPLANTS
Zhu, Agnes , Callori, Steven , Hebel, Nathan , Martinez‐Jorge, Jorys, Boonipat, Thanapoom

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 100-101

10.1097/01.gox.0000828776.79912.0c Get It

35. BROWLIFT: CORRELATION OF ARTIFICIAL INTELLIGENCE WITH EXCURSION MEASUREMENTS IN IDENTIFYING SURGICAL EFFICACY
Boonipat, Thanapoom , Hebel, Nathan , Callori, Steven , Lin, Jason , Bite, Uldis

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 1, 2022 | Volume: 10 | Issue: 4S | Pages: 18-18

10.1097/01.gox.0000828128.08724.ed Get It

The Therapeutic Potential of Exosomes in Soft Tissue Repair and Regeneration
Wan, Rou , Moran, Steven L. , Zhao, Chunfeng , Hussain, Arif , Behfar, Atta

Mayo Clinic

International Journal of Molecular Sciences | March 31, 2022 | Volume: 23 | Issue: 7 | Pages: 3869

10.3390/ijms23073869 | PMID 35409228 Get It

Soft tissue defects are common following trauma and tumor extirpation. These injuries can result in poor functional recovery and lead to a diminished quality of life. The healing of skin and muscle is a complex process that, at present, leads to incomplete recovery and scarring. Regenerative medicine may offer the opportunity to improve the healing process and functional outcomes. Barriers to regenerative strategies have included cost, regulatory hurdles, and the need for cell-based therapies. In recent years, exosomes, or extracellular vesicles, have gained tremendous attention in the field of soft tissue repair and regeneration. These nanosized extracellular particles (30–140 nm) can break the cellular boundaries, as well as facilitate intracellular signal delivery in various regenerative physiologic and pathologic processes. Existing studies have established the potential of exosomes in regenerating tendons, skeletal muscles, and peripheral nerves through different mechanisms, including promoting myogenesis, increasing tenocyte differentiation and enhancing neurite outgrowth, and the proliferation of Schwann cells. These exosomes can be stored for immediate use in the operating room, and can be produced cost efficiently. In this article, we critically review the current advances of exosomes in soft tissue (tendons, skeletal muscles, and peripheral nerves) healing. Additionally, new directions for clinical applications in the future will be discussed.
CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)
Tella, Sri Harsha , Wessling, Jaclynn, Nathan, Foster, Qian, Shi, Nguyen, Tran, McWillimas, Robert, Steven, Alberts, Liu, Minetta C. , Hartgers, Mindy L., Washburn, Leslie, Briant, Fruth, Fernández-Zapico, Martín E. , Hogenson, Tara L. , Pitot, Henry C., Qian, Shi, Borad, Mitesh J. , Wee, Wen , Jin, Zhaohui , Mahipal, Amit

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2022 | Volume: 20 | Issue: 3.5 | Pages: CLO22-088

10.6004/jnccn.2021.7328 Get It

Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
Miller, Devon , Livingston, J. Andrew , Park, Yeonhee , Posey, Kristi, Godbole, Sonia, Skubitz, Keith M. , Agulnik, Mark , Davis, Lara E. , Tine, Brian A. Van , Livingston, John A , Skubitz, Keith , Agulnik, Mark , Davis, Lara E , Van Tine, Brian A , Hirbe, Angela C , Parkes, Amanda , Robinson, Steven I. , Hirbe, Angela C.

Mayo Clinic

Cancer Medicine | March 28, 2022 | Volume: 11 | Issue: 18 | Pages: 3471-3478

10.1002/cam4.4707 | PMID 35343652 Get It

AbstractBackgroundSarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy. We sought to study the administration of anthracyclines and/or ifosfamide in pregnancy‐associated sarcomas.Patients and MethodsWe conducted a multi‐institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy. Chart review identified variables related to demographics, cancer diagnosis, therapies, and outcome of the patient and fetus. Wilcoxon rank‐sum test compared two independent samples.ResultsWe identified 13 patients at seven institutions with sarcoma who received anthracyclines and/or ifosfamide during pregnancy, including four bone sarcomas and nine soft tissue sarcomas diagnosed at a mean gestational age of 16.7 ± 5.9 weeks. Only nine patients had live births (9/13, 69.2%), with mean gestational age of 30.8 ± 3.8 weeks at delivery. The four patients with pregnancy loss all received both doxorubicin and ifosfamide, with chemotherapy initiated at 15.5 weeks as compared with 21.3 weeks for those patients with live births (p = 0.016).ConclusionIn this multi‐institutional study of sarcoma chemotherapy regimens administered during pregnancy, we found a high rate of fetal demise that was seen only in patients receiving both doxorubicin and ifosfamide and statistically more likely with chemotherapy initiation earlier in the second trimester. While limited by a small sample size, our study represents the largest study of sarcoma patients that received anthracyclines and/or ifosfamide in pregnancy thus far reported and supports development of an international registry to study concerns raised by our study.